CZ2021138A3 - Claudin6 protilátky a způsoby léčení rakoviny - Google Patents

Claudin6 protilátky a způsoby léčení rakoviny Download PDF

Info

Publication number
CZ2021138A3
CZ2021138A3 CZ2021138A CZ2021138A CZ2021138A3 CZ 2021138 A3 CZ2021138 A3 CZ 2021138A3 CZ 2021138 A CZ2021138 A CZ 2021138A CZ 2021138 A CZ2021138 A CZ 2021138A CZ 2021138 A3 CZ2021138 A3 CZ 2021138A3
Authority
CZ
Czechia
Prior art keywords
seq
amino acid
antigen binding
sequence
binding protein
Prior art date
Application number
CZ2021138A
Other languages
Czech (cs)
English (en)
Inventor
Dylan CONKLIN
Dylan Conklin
Dennis Slamon
Neil O'Brien
Neil O'brien
Mike PALAZZOLO
Mike Palazzolo
Erika VON EUW
Euw Erika Von
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CZ2021138A3 publication Critical patent/CZ2021138A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
CZ2021138A 2017-09-18 2021-03-19 Claudin6 protilátky a způsoby léčení rakoviny CZ2021138A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18

Publications (1)

Publication Number Publication Date
CZ2021138A3 true CZ2021138A3 (cs) 2021-09-15

Family

ID=65723110

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ2021138A CZ2021138A3 (cs) 2017-09-18 2021-03-19 Claudin6 protilátky a způsoby léčení rakoviny

Country Status (22)

Country Link
US (4) US20200291111A1 (https=)
EP (2) EP4435009A3 (https=)
JP (2) JP7599332B2 (https=)
KR (2) KR20250050137A (https=)
CN (2) CN118667021A (https=)
AU (2) AU2018334434B2 (https=)
BR (1) BR112020005196A2 (https=)
CA (1) CA3076207A1 (https=)
CZ (1) CZ2021138A3 (https=)
DK (1) DK3826667T3 (https=)
ES (1) ES2986343T3 (https=)
FI (1) FI3826667T3 (https=)
GB (1) GB202103867D0 (https=)
HU (1) HUE067603T2 (https=)
IL (2) IL273196B2 (https=)
MX (2) MX2020002921A (https=)
NO (1) NO20210351A1 (https=)
PL (1) PL3826667T3 (https=)
PT (1) PT3826667T (https=)
SG (1) SG11202002114RA (https=)
SI (1) SI3826667T1 (https=)
WO (1) WO2019056023A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL273196B2 (en) * 2017-09-18 2024-11-01 Univ California Claudin6 antibodies and methods of treating cancer
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
JP7682797B2 (ja) * 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
AU2020241896A1 (en) * 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
WO2023091512A2 (en) * 2021-11-16 2023-05-25 Allakos, Inc. Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
KR20240153421A (ko) * 2022-02-09 2024-10-22 세라 프로그노스틱스 인코포레이티드 Shbg 및 ibp4 항체 및 이를 사용하는 방법
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025075127A1 (ja) * 2023-10-04 2025-04-10 公立大学法人福島県立医科大学 がんのバイオマーカー及び抗体治療
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
CA2346866A1 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
DE60331455D1 (de) 2002-10-04 2010-04-08 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
JP5632582B2 (ja) * 2006-12-14 2014-11-26 中外製薬株式会社 抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
NZ580700A (en) 2007-04-19 2012-01-12 Dong A Pharm Co Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US9321842B2 (en) * 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
PE20160870A1 (es) * 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
SI3126381T2 (sl) * 2014-04-01 2022-05-31 Biontech Cell&Gene Therapies Gmbh Claudin-6-specifični imunoreceptorji in t-celični epitopi
IL273196B2 (en) * 2017-09-18 2024-11-01 Univ California Claudin6 antibodies and methods of treating cancer

Also Published As

Publication number Publication date
PL3826667T3 (pl) 2024-09-30
BR112020005196A2 (pt) 2020-09-15
SI3826667T1 (sl) 2024-09-30
GB202103867D0 (en) 2021-05-05
JP7599332B2 (ja) 2024-12-13
AU2018334434A1 (en) 2020-04-02
IL313238A (en) 2024-07-01
SG11202002114RA (en) 2020-04-29
IL273196A (en) 2020-04-30
WO2019056023A2 (en) 2019-03-21
IL273196B2 (en) 2024-11-01
AU2018334434B2 (en) 2025-01-23
WO2019056023A3 (en) 2019-05-16
CN111565744A (zh) 2020-08-21
EP4435009A2 (en) 2024-09-25
KR20250050137A (ko) 2025-04-14
EP4435009A3 (en) 2025-02-26
US20250333501A1 (en) 2025-10-30
CN111565744B (zh) 2024-12-31
US20200291111A1 (en) 2020-09-17
MX2020002921A (es) 2020-09-28
FI3826667T3 (fi) 2024-07-22
EP3826667A4 (en) 2022-07-27
JP2020536507A (ja) 2020-12-17
EP3826667A2 (en) 2021-06-02
HUE067603T2 (hu) 2024-10-28
EP3826667B1 (en) 2024-04-17
AU2025200467A1 (en) 2025-04-10
KR102793719B1 (ko) 2025-04-08
IL273196B1 (en) 2024-07-01
KR20200070238A (ko) 2020-06-17
US20240400674A1 (en) 2024-12-05
NO20210351A1 (en) 2021-03-18
PT3826667T (pt) 2024-08-02
JP2024150445A (ja) 2024-10-23
MX2025012685A (es) 2025-11-03
CA3076207A1 (en) 2019-03-21
ES2986343T3 (es) 2024-11-11
CN118667021A (zh) 2024-09-20
DK3826667T3 (da) 2024-07-22
US20220372134A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
AU2018334434B2 (en) Claudin6 antibodies and methods of treating cancer
JP2025122027A (ja) クローディン６二重特異性抗体
JP2025122026A (ja) クローディン６抗体及び薬物複合体
JP7595696B2 (ja) Ｃｄ３抗原結合性断片及びその使用
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
CN111018987B (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
CN114478768B (zh) 抗cd73的抗体及其用途
KR20140032992A (ko) Ｃｓｆ－1ｒ에 대한 항체
WO2020151762A1 (zh) 新型双特异性抗体分子以及同时结合pd-l1和lag-3的双特异性抗体
US20230331842A1 (en) Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
JP7745657B2 (ja) 抗ｐｄ－１ヒト化抗体又はその抗原結合性断片及びその使用
TW201121569A (en) Treatment of cancer involving mutated KRAS or BRAF genes
JP2025534367A (ja) 抗ｆｇｆｒ２ｂ抗体及びその使用
CN113121689B (zh) Ctla-4结合分子及其用途
CN103374072B (zh) 一种抗Mac‑2BP人源化抗体的制备
RU2778053C2 (ru) Антитела к lag3
WO2025209572A1 (zh) 抗il-1rap抗体、其药物组合物及用途
EA051023B1 (ru) Фармацевтическая композиция и набор, содержащие антитело против cd73, и их применение в способе лечения опухоли
HK40084729A (en) Anti-flt3 antibodies and compositions
HK40024246A (en) An antibody that specifically binds to human endothelin receptor and use thereof